Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello; European Society of Retina Specialists

doi:10.1136/bjophthalmol-2014-305702

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello, European Society of Retina Specialists

Department of Clinical Medicine

257 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients.

Original language	English
Journal	British Journal of Ophthalmology
Volume	98
Issue number	9
Pages (from-to)	1144-1167
Number of pages	24
ISSN	0007-1161
DOIs	https://doi.org/10.1136/bjophthalmol-2014-305702
Publication status	Published - Sept 2014

Keywords

Angiogenesis Inhibitors
Choroidal Neovascularization
Evidence-Based Medicine
Humans
Light Coagulation
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
Wet Macular Degeneration

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bjophthalmol-2014-305702

Cite this

Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., Bandello, F., & European Society of Retina Specialists (2014). Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology, 98(9), 1144-1167. https://doi.org/10.1136/bjophthalmol-2014-305702

Schmidt-Erfurth, U, Chong, V, Loewenstein, A, Larsen, M, Souied, E, Schlingemann, R, Eldem, B, Monés, J, Richard, G, Bandello, F & European Society of Retina Specialists 2014, 'Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)', British Journal of Ophthalmology, vol. 98, no. 9, pp. 1144-1167. https://doi.org/10.1136/bjophthalmol-2014-305702

@article{f3c84cf324014a51becc2c373e9ad48c,

title = "Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)",

abstract = "Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients.",

keywords = "Angiogenesis Inhibitors, Choroidal Neovascularization, Evidence-Based Medicine, Humans, Light Coagulation, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration",

author = "Ursula Schmidt-Erfurth and Victor Chong and Anat Loewenstein and Michael Larsen and Eric Souied and Reinier Schlingemann and Bora Eldem and Jordi Mon{\'e}s and Gisbert Richard and Francesco Bandello and {European Society of Retina Specialists}",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",

year = "2014",

month = sep,

doi = "10.1136/bjophthalmol-2014-305702",

language = "English",

volume = "98",

pages = "1144--1167",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "B M J Group",

number = "9",

}

TY - JOUR

T1 - Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

AU - Schmidt-Erfurth, Ursula

AU - Chong, Victor

AU - Loewenstein, Anat

AU - Larsen, Michael

AU - Souied, Eric

AU - Schlingemann, Reinier

AU - Eldem, Bora

AU - Monés, Jordi

AU - Richard, Gisbert

AU - Bandello, Francesco

AU - European Society of Retina Specialists

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2014/9

Y1 - 2014/9

N2 - Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients.

AB - Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients.

KW - Angiogenesis Inhibitors

KW - Choroidal Neovascularization

KW - Evidence-Based Medicine

KW - Humans

KW - Light Coagulation

KW - Tomography, Optical Coherence

KW - Vascular Endothelial Growth Factor A

KW - Wet Macular Degeneration

U2 - 10.1136/bjophthalmol-2014-305702

DO - 10.1136/bjophthalmol-2014-305702

M3 - Journal article

C2 - 25136079

SN - 0007-1161

VL - 98

SP - 1144

EP - 1167

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

IS - 9

ER -

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this